Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by enriquesuave on Sep 29, 2020 4:35pm

Nice Read

One of our future Photosensitisors thanks to Sherri.  May have already been posted


https://pubs.rsc.org/en/Content/ArticleLanding/2020/SC/D0SC03008B#!divAbstract

Comment by Sunvalley on Sep 29, 2020 5:04pm
Nice read you say?? Chemistry was never my forte during my learning years. After reading the submission in detail I felt compelled to go out on my front lawn and do cartwheels and with each revolution I consumed a mouthful of grass LOL 
Comment by Yajne on Sep 29, 2020 5:15pm
The efficacy just keeps getting better with the new  Os based PS's. Skimmed across to conclusions but will have to circle back and read to attempt to digest some of the details.  One thing I did note near the end was the Conflict of Interest statement: S. A. M. has a potential research conflict of interest due to a financial interest with Theralase Technologies, Inc. and ...more  
Comment by Hempdoc on Sep 29, 2020 5:19pm
Thanks for posting...more sweet validation as our pharmaceutical "assets" continue to grow/excite, not to mention the sweet glitter of osmium to end the day....TLT has it covered : ).  
Comment by Eoganacht on Sep 29, 2020 5:41pm
That's a gooden. Hopefully Theralase will get to Os-4T eventually. But whether or not, the research still increases Theralase's IP.   "Here we introduce an Os(II)-based PS (Os-4T) that is extremely potent, can be activated with near-infrared light (NIR, 733 nm), and exhibits photocytotoxic effects in hypoxia (1% O2)."
Comment by investclub on Sep 29, 2020 8:36pm
Thanks enriquesuave  Quite mind boggling to read but what I did grasp is the incredible amount of work has gone into developing not only TDL-1433 but to try and get my mind around this possible new improved compound . Yes amazing is an understatement. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250